REAL life study of subcutaneous SEMaglutide in patients with type 2 diabetes in SPain: Ambispective, multicenter clinical study. Results in the GLP1-experienced cohort.

Autor: Cárdenas-Salas JJ; Hospital Universitario Fundación Jiménez Díaz, Avda. Reyes Católicos, 2, CP 28040 Madrid, Madrid, Spain; Hospital Universitario Infanta Elena, Avda. Reyes Católicos 21, CP 28340 Valdemoro, Madrid, Spain; Instituto de Investigación Sanitaria Fundación Jiménez-Díaz (IIS-FJD), Universidad Autónoma de Madrid (UAM), Hospital Universitario Fundación Jiménez Díaz, Avda. Reyes Católicos, 2, CP 28040 Madrid, Madrid, Spain. Electronic address: jersy.cardenas@quironsalud.es., Sierra Poyatos RM; Hospital Universitario Fundación Jiménez Díaz, Avda. Reyes Católicos, 2, CP 28040 Madrid, Madrid, Spain; Hospital Universitario General de Villalba, Carretera de Alpedrete a Moralzarzal M-608 Km 41. CP2 8400 Collado Villalba, Madrid, Spain., Luca BL; Hospital Universitario Fundación Jiménez Díaz, Avda. Reyes Católicos, 2, CP 28040 Madrid, Madrid, Spain., Sánchez Lechuga B; Hospital Universitario Fundación Jiménez Díaz, Avda. Reyes Católicos, 2, CP 28040 Madrid, Madrid, Spain., Modroño Móstoles N; Hospital Universitario Infanta Elena, Avda. Reyes Católicos 21, CP 28340 Valdemoro, Madrid, Spain., Montoya Álvarez T; Hospital Universitario Infanta Elena, Avda. Reyes Católicos 21, CP 28340 Valdemoro, Madrid, Spain., Gómez Montes MP; Hospital Universitario Infanta Elena, Avda. Reyes Católicos 21, CP 28340 Valdemoro, Madrid, Spain., Ruiz Sánchez JG; Hospital Universitario Fundación Jiménez Díaz, Avda. Reyes Católicos, 2, CP 28040 Madrid, Madrid, Spain; Instituto de Investigación Sanitaria Fundación Jiménez-Díaz (IIS-FJD), Universidad Autónoma de Madrid (UAM), Hospital Universitario Fundación Jiménez Díaz, Avda. Reyes Católicos, 2, CP 28040 Madrid, Madrid, Spain., Meneses González D; Hospital Universitario Fundación Jiménez Díaz, Avda. Reyes Católicos, 2, CP 28040 Madrid, Madrid, Spain; Instituto de Investigación Sanitaria Fundación Jiménez-Díaz (IIS-FJD), Universidad Autónoma de Madrid (UAM), Hospital Universitario Fundación Jiménez Díaz, Avda. Reyes Católicos, 2, CP 28040 Madrid, Madrid, Spain., Sánchez-Lopez R; Hospital Universitario Fundación Jiménez Díaz, Avda. Reyes Católicos, 2, CP 28040 Madrid, Madrid, Spain; Hospital Universitario Infanta Elena, Avda. Reyes Católicos 21, CP 28340 Valdemoro, Madrid, Spain., Casado Cases C; Hospital Universitario Fundación Jiménez Díaz, Avda. Reyes Católicos, 2, CP 28040 Madrid, Madrid, Spain., Pérez de Arenaza Pozo V; Hospital Universitario Fundación Jiménez Díaz, Avda. Reyes Católicos, 2, CP 28040 Madrid, Madrid, Spain., Vázquez Martínez C; Hospital Universitario Fundación Jiménez Díaz, Avda. Reyes Católicos, 2, CP 28040 Madrid, Madrid, Spain; Hospital Universitario Infanta Elena, Avda. Reyes Católicos 21, CP 28340 Valdemoro, Madrid, Spain; Hospital Universitario General de Villalba, Carretera de Alpedrete a Moralzarzal M-608 Km 41. CP2 8400 Collado Villalba, Madrid, Spain; Hospital Universitario Rey Juan Carlos, Gladiolo s/n, CP 28933 Móstoles, Madrid, Spain; Instituto de Investigación Sanitaria Fundación Jiménez-Díaz (IIS-FJD), Universidad Autónoma de Madrid (UAM), Hospital Universitario Fundación Jiménez Díaz, Avda. Reyes Católicos, 2, CP 28040 Madrid, Madrid, Spain.
Jazyk: angličtina
Zdroj: Journal of diabetes and its complications [J Diabetes Complications] 2024 Dec; Vol. 38 (12), pp. 108874. Date of Electronic Publication: 2024 Sep 17.
DOI: 10.1016/j.jdiacomp.2024.108874
Abstrakt: Objective: To evaluate the efficacy of switching to once-weekly subcutaneous semaglutide in patients with type 2 diabetes mellitus (T2DM) who were previously treated with other glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in a real-world setting in Spain.
Methods: The REAL Life study of SEMaglutide in Patients with Type 2 diabetes in Spain (REALSEM-SP) was conducted in four endocrinology departments in Madrid, Spain. Adult patients with T2DM who were prescribed once-weekly (OW) subcutaneous semaglutide and had been previously treated with other GLP-1 RAs were included. Baseline characteristics, including demographic, anthropometric, and laboratory variables, were recorded at baseline and at 6 ± 3 and 12 ± 3 months of follow-up. The primary outcome was the change in HbA 1c at 12 ± 3 months of follow-up, with secondary outcomes including changes in weight, BMI, and other glycemic parameters.
Results: A total of 267 patients were included in the analysis, with a mean age of 61.6 years and a mean T2DM duration of 11.3 years. The majority of patients had grade 1 or 2 obesity at baseline. Switching to OW-semaglutide was associated with a significant reduction in HbA 1c from baseline to 13 months (-0.35 % ± 0.81). Patients who reached the 1.0 mg OW-dose showed a significant reduction in HbA 1c compared to those on the ≤0.5 mg OW-dose. Significant reductions in weight, BMI, and fasting plasma glucose were also observed. Adverse events were mostly gastrointestinal and led to treatment withdrawal in few cases.
Conclusion: Switching to OW-subcutaneous semaglutide in patients with T2DM previously treated with other GLP-1 RAs was associated to improvements in glycemic control and weight management in a real-world setting in Spain. These findings support the use of OW-semaglutide as an effective option for patients with T2DM who require additional glycemic control and weight management.
Competing Interests: Declaration of competing interest JCS has received speaker honoraria from Novonordisk, Sanofi, Boehringher- Ingelheim & Lilly, Astrazeneca, Almirall, and Mundipharma. JCS has received funding to attend medical conferences from Novonordisk, Boehringher- Ingelheim & Lilly, Almirall, Sanofi and Recordati Rare diseases. TMA has received funding to attend medical conferences from Novonordisk. JGRS and CVM have received speaker honoraria and funding to attend medical conferences from Novonordisk. RMSP, BLL, BSL, NMM, MGM, DMG, RSL, CCC and VPAP have nothing to disclose.
(Copyright © 2024 Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: